ALTAMIRA THERAPEUTICS LTD (CYTO) Fundamental Analysis & Valuation

NASDAQ:CYTO • BMG0360L1349

Current stock price

0.3 USD
-0.11 (-25.94%)
At close:
0.262 USD
-0.04 (-12.67%)
After Hours:

This CYTO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. CYTO Profitability Analysis

1.1 Basic Checks

  • In the past year CYTO was profitable.
  • In the past year CYTO had a positive cash flow from operations.
  • In the past 5 years CYTO always reported negative net income.
  • CYTO had a negative operating cash flow in each of the past 5 years.
CYTO Yearly Net Income VS EBIT VS OCF VS FCFCYTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • CYTO's Return On Assets of -0.09% is amongst the best of the industry. CYTO outperforms 82.20% of its industry peers.
  • CYTO has a Return On Equity of -0.11%. This is amongst the best in the industry. CYTO outperforms 82.72% of its industry peers.
Industry RankSector Rank
ROA -0.09%
ROE -0.11%
ROIC N/A
ROA(3y)-179.21%
ROA(5y)-129.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTO Yearly ROA, ROE, ROICCYTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CYTO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTO Yearly Profit, Operating, Gross MarginsCYTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CYTO Health Analysis

2.1 Basic Checks

  • CYTO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CYTO has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, CYTO has an improved debt to assets ratio.
CYTO Yearly Shares OutstandingCYTO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M
CYTO Yearly Total Debt VS Total AssetsCYTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

  • CYTO has an Altman-Z score of 1.19. This is a bad value and indicates that CYTO is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of CYTO (1.19) is better than 60.21% of its industry peers.
  • The Debt to FCF ratio of CYTO is 0.09, which is an excellent value as it means it would take CYTO, only 0.09 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.09, CYTO belongs to the top of the industry, outperforming 96.86% of the companies in the same industry.
  • CYTO has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • CYTO's Debt to Equity ratio of 0.05 is in line compared to the rest of the industry. CYTO outperforms 51.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.09
Altman-Z 1.19
ROIC/WACCN/A
WACC7.3%
CYTO Yearly LT Debt VS Equity VS FCFCYTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 0.43 indicates that CYTO may have some problems paying its short term obligations.
  • The Current ratio of CYTO (0.43) is worse than 95.81% of its industry peers.
  • CYTO has a Quick Ratio of 0.43. This is a bad value and indicates that CYTO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CYTO has a worse Quick ratio (0.43) than 95.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.43
Quick Ratio 0.43
CYTO Yearly Current Assets VS Current LiabilitesCYTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CYTO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 101.44% over the past year.
  • The Revenue for CYTO has decreased by -79.76% in the past year. This is quite bad
EPS 1Y (TTM)101.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.56%
Revenue 1Y (TTM)-79.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -4.65% on average over the next years.
  • Based on estimates for the next years, CYTO will show a very strong growth in Revenue. The Revenue will grow by 214.13% on average per year.
EPS Next Y-88.67%
EPS Next 2Y8.03%
EPS Next 3Y-4.65%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y214.13%
Revenue Next 5YN/A

3.3 Evolution

CYTO Yearly Revenue VS EstimatesCYTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2026 1M 2M 3M 4M 5M
CYTO Yearly EPS VS EstimatesCYTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2024 2025 2026 -1K -2K -3K -4K

More info and screens

Find the best growth stocksShow best growing peers

4

4. CYTO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 0.36, which indicates a rather cheap valuation of CYTO.
  • CYTO's Price/Earnings ratio is rather cheap when compared to the industry. CYTO is cheaper than 99.48% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.91, CYTO is valued rather cheaply.
  • The Forward Price/Earnings Ratio is negative for CYTO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 0.36
Fwd PE N/A
CYTO Price Earnings VS Forward Price EarningsCYTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

  • CYTO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CYTO is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 0.25
EV/EBITDA N/A
CYTO Per share dataCYTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • CYTO's earnings are expected to decrease with -4.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.03%
EPS Next 3Y-4.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CYTO Dividend Analysis

5.1 Amount

  • CYTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CYTO Fundamentals: All Metrics, Ratios and Statistics

ALTAMIRA THERAPEUTICS LTD

NASDAQ:CYTO (12/19/2024, 10:21:17 PM)

After market: 0.262 -0.04 (-12.67%)

0.3

-0.11 (-25.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-10
Earnings (Next)N/A
Inst Owners0.13%
Inst Owner Change0%
Ins Owners0.53%
Ins Owner ChangeN/A
Market Cap1.13M
Revenue(TTM)62.75K
Net Income(TTM)-7.24K
Analysts82.86
Price Target5.41 (1703.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-35.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)31.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.36
Fwd PE N/A
P/S 18.07
P/FCF 0.25
P/OCF 0.25
P/B 0.18
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)0.83
EY276.67%
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)1.22
FCFY406.8%
OCF(TTM)1.22
OCFY406.8%
SpS0.02
BVpS1.67
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.09%
ROE -0.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 7351.86%
ROA(3y)-179.21%
ROA(5y)-129.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.09
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.43
Quick Ratio 0.43
Altman-Z 1.19
F-Score6
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)1981.94%
Cap/Depr(5y)5522.5%
Cap/Sales(3y)2080.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)101.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.56%
EPS Next Y-88.67%
EPS Next 2Y8.03%
EPS Next 3Y-4.65%
EPS Next 5YN/A
Revenue 1Y (TTM)-79.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y214.13%
Revenue Next 5YN/A
EBIT growth 1Y98.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y126.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y132.19%
OCF growth 3YN/A
OCF growth 5YN/A

ALTAMIRA THERAPEUTICS LTD / CYTO Fundamental Analysis FAQ

What is the fundamental rating for CYTO stock?

ChartMill assigns a fundamental rating of 3 / 10 to CYTO.


Can you provide the valuation status for ALTAMIRA THERAPEUTICS LTD?

ChartMill assigns a valuation rating of 4 / 10 to ALTAMIRA THERAPEUTICS LTD (CYTO). This can be considered as Fairly Valued.


Can you provide the profitability details for ALTAMIRA THERAPEUTICS LTD?

ALTAMIRA THERAPEUTICS LTD (CYTO) has a profitability rating of 2 / 10.


Can you provide the financial health for CYTO stock?

The financial health rating of ALTAMIRA THERAPEUTICS LTD (CYTO) is 3 / 10.


Can you provide the expected EPS growth for CYTO stock?

The Earnings per Share (EPS) of ALTAMIRA THERAPEUTICS LTD (CYTO) is expected to decline by -88.67% in the next year.